Drugs and Cosmetics Act 1940

Drugs and Cosmetics Act, 1940 — the cornerstone of India’s regulatory architecture for medicines, vaccines, medical devices and personal‑care products, it prescribes the conditions under which these items may be imported, manufactured, distributed and sold, and empowers a dedicated authority to enforce safety, efficacy and quality standards across the nation’s vast pharmaceutical landscape. Enacted by the Imperial Legislative Council on 1 March 1940, the Act introduced a unified legal definition of “drug” and “cosmetic”, mandated batch‑wise labeling, and created the institutional framework that later evolved into the Central Drugs Standard Control Organization (CDSCO).

Origins and Legislative Evolution

The 1940 statute replaced a patchwork of colonial ordinances and was the first comprehensive attempt to control both therapeutic and non‑therapeutic products in British India. Its drafting drew on the United Kingdom’s Medicines Act 1928 and the United States’ Food, Drug, and Cosmetic Act 1938, adapting those models to Indian market realities such as the prevalence of traditional remedies. After independence, the Act was retained with minor modifications, and the Constitution’s Directive Principles (Article 47) reinforced the legislative intent to safeguard public health.

Core Mechanism and Institutional Framework

Administration rests with the Drugs Controller General of India (DCGI), who heads the CDSCO under the Ministry of Health and Family Welfare. The DCGI issues licences, conducts inspections, and adjudicates violations, while each state appoints a State Drug Controller to enforce the Act locally. The licensing regime is tiered: Section 18 governs manufacturing licences, Section 20 wholesale licences, Section 21 retail licences, and Section 22 import licences, each requiring proof of Good Manufacturing Practice (GMP) compliance and periodic renewal.

Key Provisions

Section 6 defines a “drug” as any substance intended for diagnosis, treatment, mitigation or prevention of disease, including biologics and medical devices; Section 8 defines a “cosmetic” as any article intended for cleansing, beautifying or altering the appearance of the human body. Section 12 obliges every drug package to display a batch number, manufacturing date and expiry date, a requirement that underpins traceability during recalls. Sections 27‑30 empower authorities to seize spurious or adulterated products, issue prohibition orders, and prosecute offenders; penalties under Section 38 range from a fine of up to ₹10 lakh to imprisonment for up to five years, with higher punishments introduced by the 2008 amendment for repeat violations.

India’s Regulatory Journey

The Act has been amended more than twenty times, reflecting the sector’s rapid growth. The Drugs (Amendment) Act 2008 introduced provisions for clinical trials, new‑drug approvals and the categorisation of “new chemical entities”. The 2016 amendment tightened penalties, added Schedule H1 for antibiotics, and mandated electronic record‑keeping for manufacturers. In 2020, the Act was extended to cover e‑pharmacies and to provide a transitional regulatory umbrella for medical devices until the separate Medical Devices Rules 2017 took effect. Throughout, the CDSCO has expanded its workforce to over 2,500 technical staff and conducts roughly 1 million inspections annually.

Current Implementation and Challenges

As of 2023, more than 30,000 manufacturing licences and 1.5 lakh retail licences are active, supporting India’s status as the world’s third‑largest pharmaceutical exporter. The Act’s enforcement is bolstered by digital tools such as the “SUGAM” portal for licence applications and the “e‑Sanjeevani” platform for adverse‑event reporting. Nevertheless, challenges persist: the proliferation of online drug sales strains the Act’s traditional inspection model, and the coexistence of parallel regulatory regimes for medical devices creates compliance ambiguities. Ongoing legislative reviews aim to harmonise the Act with the New Drugs and Clinical Trials Rules 2019 and to introduce risk‑based surveillance, ensuring that the 1940 framework remains fit for a 21st‑century health ecosystem.